Large-scale analysis shows Pfizer-BioNTech vaccine highly effective against COVID-19
A large-scale study conducted in Israel has found that the Pfizer-BioNTech COVID-19 vaccine is highly effective in preventing infections, severe illness, and death. The study analyzed data from more than 1.3 million people, including over 650,000 fully vaccinated individuals, and found that the vaccine was 96.7% effective in preventing symptomatic COVID-19 infections, 98% effective in preventing hospitalizations, and 98.1% effective in preventing death. The study also found that the vaccine remained highly effective against the highly transmissible Delta variant, with an effectiveness of 94.5% in preventing symptomatic infections. These findings provide further evidence of the effectiveness of the Pfizer-BioNTech vaccine and support ongoing vaccination efforts.